

ASX Release

SUDA APPOINTS DAVID PHILLIPS AS ADVISOR TO THE BOARD

PERTH, AUSTRALIA – 28 November 2017: SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, has appointed David Phillips as an Advisor to the Board. David will commence this role on 1 December 2017.

David has spent over 30 years in the global healthcare industry including 14 years in sales and marketing with Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc, and latterly eight years with SR One (GSK's Corporate Venture Fund).

In between these two periods with GSK, David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC (prior to the divestment to Galapagos NV where he stayed with the business). David re-joined GlaxoSmithKline's (GSK) SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early stage life science companies.

He has divested a number of R&D operations and drug delivery technologies and he led the team that divested GSK's opiates business in Australia in 2015. David is currently a senior investment manager at BioScience Managers Pty Ltd, a leading life sciences investment firm, head-quartered in Melbourne.

SUDA's CEO, Mr Stephen Carter, commented: "We are delighted that David Phillips will be joining us as an Advisor to the Board. David brings a wealth of international experience from within large pharmaceutical and small biopharma companies. With his knowledge and network of pharma and investment professionals, David will be a valuable addition to the team."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA Ltd
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA Ltd

SUDA Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudaltd.com.au